Full Press Release Details
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to ten newly hired non-executive employees consisting of options to purchase an aggregate of 269,800 common shares of the Company (the "Options") with effective grant dates of November 9, 20